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both hyperglycaemia and hypoglycaemia are unwanted 
phenomena.
Sulfonylureas are the drugs of choice in the treatment of 
type 2 diabetes.[1] Currently, gliclazide, a second-generation 
sulfonylurea, is preferred in therapy because of its selective 
inhibitory activity toward pancreatic K+ATP channels,[2] 
low incidence of producing severe hypoglycemia[3] and 
other hemobiological effects.[4] It is well established that 
sulfonylureas produce insulin secretion and improve tissue 
utilization of glucose at the cellular level,[5] which was 
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A study of the mechanisms of drug interactions is 
of much value in selecting the drug combinations to 
provide rational therapy. The drug interaction studies 
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prolonged periods, and maintenance of normal blood 
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ABSTRACT
Diabetes mellitus is a condition of increased blood glucose level in the body. Antihyperlipidemic drugs like statins 
and fibrates are widely used for prophylactic treatment in dyslipideamia and atherosclerosis. Diabetic dislipidemia 
exists with increased triglycerides, low HDL  and high LDL levels. Hence, with oral hypoglycemic drugs, the 
addition of a lipid-lowering drug is necessary for controlling dislipidemia. In such a situation, there may be chances 
of drug–drug interactions between antidiabetic and antihyperlipidemic drugs. The present study is planned to 
evaluate the safety of gliclazide (antidiabetic) in the presence of pravastatin and gemfibrozil (antihyperlpidemic) 
in rats. Studies in normal and alloxan-induced diabetic rats were conducted with oral doses of gliclazide and 
their combination with pravastatin and gemfibrozil, with an adequate washout period in between the treatments. 
Blood samples were collected in rats by retroorbital puncture at 0, 1, 2, 3, 4, 6, 8, 10 and 12 h. All the blood 
samples were analyzed for glucose by GOD –POD. Gliclazide (½ TD) produced hypoglycemic activity in normal 
and diabetic rats, with peak activity at 2 and 8 h. Pravastatin (TD) + gemfibrozil (TD) combination treatment 
increased the hypoglycemic effect of gliclazide in normal rats or diabetic rats when administered together. The 
interaction observed due to inhibition of both the enzymes (CYP 450 2C9 and CYP 450 3A4) responsible for the 
metabolism of gliclazide showed increased half-life, which was seen in the present study. Because concomitant 
administration of gliclazide with provastatin and gemfibrozil in diabetes is associated with atherosclerosis, it 
should be contraindicated or used with caution.
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responsible for lowering of the blood glucose level. The 
sulfonylureas and related drugs used in type 2 diabetes 
stimulate insulin by closing K+ATP channels in pancreatic 
β cells.
Antihyperlipidemic drugs like statins and fibrates are 
widely used for prophylactic treatment in dyslipidemia 
and atherosclerosis. Pravastatin is known to inhibit 
liver microsomal enzyme CYP 450 3A4, CYP 2C9 and 
CYP 2D6.[6,7] Gemfibrozil is metabolized by the hepatic 
cytochrome CYP 450 2C9.[8]
Hence, there is a higher possibility of pravastatin and 
gemfibrozil for inhibition of the metabolism of gliclazide, 
because they are also metabolized by both CYP 450 2C9 
and CYP 3A4.[9]
Because concomitant administration of gliclazide with 
pravastatin and gemfibrozil in diabetes is associated with 
atherosclerosis, there is every possibility for drug–drug 
interaction with enhanced or decreased gliclazide activity, 
which is unwanted.
The safety of the above drug combinations with respect 
to blood glucose is not known and needs to be established 
by preclinical and clinical studies. This study is planned to 
establish the safety of the drug combinations in the rat 
model with respect to blood glucose level and find out the 
mechanisms responsible for the interaction, if any.
MATERIALS AND METHODS
Drugs and chemicals
Gliclazide, gemfibrozil and pravastatin are gift samples 
from Micro Labs (Bangalore, India) and Biocon 
(Bangalore, India). Alloxan monohydrate was purchased 
from Sigma Aldrich (Bommasandra, Jigni, and Bangalore, 
India). Glucose kits of span diagnostics were procured 
from local suppliers. All of the chemicals used are of 
analytical grade.
Animals
Albino rats of either sex, weighing between 160 and 280 g, 
procured from Drugs Testing Lab, Bangalore, India, were 
used in the study. They were maintained under standard 
laboratory conditions at an ambient temperature of 25 ± 
2ºC, with 12-h light/12-h dark cycles. They were fed with 
standard pellet diet (Venkateshwar Enterprises Pvt. Ltd., 
Bangalore, India) and water ad libitum. Animals were fasted 
for 18 h before the experiment and, during the experiment, 
they were withdrawn from food and water. Prior approval 
for conducting experiments on rats was obtained from our 
Institutional Animal Ethics Committee and our laboratory 
is approved by CPCSEA, Govt. of India (Regd. No. GCP/
CPCSEA/04/2005-06).
Method
Pharmacodynamic study in normal or diabetic rats
A group of six rats were administered (½ TD) 0.72 
mg/200 g of bd wt of gliclazide orally. The same group 
was administered with pravastatin (TD) 0.72 mg/200 g bd 
wt and gemfibrozil (TD) 21.6 mg/200 g bd wt orally in 
combination with gliclazide. A 1-week washout period was 
maintained between the treatments. The same treatment 
was repeated in a group of six alloxan-induced diabetic rats. 
Blood samples were withdrawn by retroorbital puncture[10] 
at 0, 1, 2, 3, 4, 6, 8, 10 and 12 h and were analysed for blood 
glucose by the GOD or POD method[11] using commercial 
glucose kits (Span Diagnostics).
Induction of  diabetes
Diabetes was induced in rats by the administration of 
alloxan monohydrate in two doses, i.e. 100 mg and 50 
mg/kg bd wt intraperitoneally for two consecutive days.[12]
Data and statistical analysis
Data were expressed as mean ± standard error of mean 
(SEM). The significance was determined by applying 
Student’s paired t-test.
RESULTS
Gliclazide produced biphasic hypoglycaemic activity, 
with maximum reduction of 38.51 ± 1.65% and 37.29 ± 
3.48% at 2 and 8 h in normal rats [Table 1, Figure 1], and 
hypoglycemic activity with maximum reduction of 37.61 
± 0.38% and 38.12 ± 1.47% at 2 and 8 h in diabetic rats 
[Table 2, Figure 2], respectively. Gliclazide, when given in 
combination with pravastatin and gemfibrozil, produced 
increased hypoglycemic effect with maximum reduction of 
51.44 ± 2.10% and 53.19 ± 1.72% and 57.18 ± 0.81% and 
56.27 ± 0.56% in the blood glucose in normal and diabetic 
rats at 2 and 8 h, respectively.
DISCUSSION
Drug interactions are usually seen in clinical practice, and 
the mechanisms of interactions are usually evaluated in 
animal models. We studied the influence of gemfibrozil 
and pravastatin on the pharmacodynamics of gliclazide in 
normal and diabetic rats. The normal rat model served to 
quickly identify the interaction and the diabetic rat model 
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served to validate the same response in the actually used 
condition of the drug.
Gliclazide produced a biphasic response in the rat model 
when administered alone, which may due to its biliary 
excretion and enterohepatic circulation in rats[13,14] and in 
humans.[15] Gliclazide is known to produce a hypoglycemic 
activity by pancreatic[16] (stimulating insulin secretion 
by blocking K+ channels in the pancreatic β cells) and 
extrapancreatic[17] (increasing tissue uptake of glucose) 
mechanisms.
Pravastatin and gemfibrozil enhanced hypoglycemic effects 
produced by gliclazide in normal and diabetic rats when 
administered in combination. This may be due to their 
activity on insulin secretion.
Because pravastatin is known to inhibit liver microsomal 
enzymes CYP 450 3A4, CYP 450 2C9 and CYP 450 
2D6 and gemfibrozil is known to be metabolized to a 
major extent by CYP 450 2C9, by which gliclazide is also 
metabolized primarily and, to a lesser extent, by CYP 
450 3A4, the interaction might be at the level of their 
metabolism. Pravastatin and gemfibrozil might compete 
with gliclazide for metabolism by CYP 450 2C9 and CYP 
450 3A4 and delay the metabolism of gliclazide, leading to 
its enhanced effect. The metabolites of gliclazide, namely 
hydroxy and carboxy gliclazide, are pharmacologically 
inactive. Hence, inhibition of gliclazide metabolism 
improves its unchanged level and pharmacological action, 
which is seen in the present study.
However, the drug pravastatin and gemfibrozil combination 
treatment did not change the pattern of biphasic response 
of gliclazide, indicating that it did not interfere with the 
reabsorption of gliclazide in its enterohepatic circulation 
in rats.
Figure 1: The mean percent blood glucose change with gliclazide 
alone and gliclazide + pravastatin + gemfibrozil combination in normal 
rats (n = 6)
Figure 2: The mean percent blood glucose change with gliclazide 
alone and gliclazide + pravastatin + gemfibrozil combination in diabetic 
rats (n = 6)
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Table 1: Mean percent blood glucose change after 
oral administration of gliclazide alone and gliclazide + 
pravastatin + gemfibrozil combination in normal rats  
(n = 6)
Time (h)  Gliclazide (1/2 TD)  Gliclazide (1/2 TD) + 
    Pravastatin (TD) +  
    Gemfibrozil (TD)
0  -  -
1  -29.89 ± 2.24  -35.33 ± 1.90
2  -38.51 ± 1.65  -51.44 ± 2.10**
3  -21.02 ± 1.65  -45.73 ± 1.65***
4  -18.50 ± 3.40  -46.67 ± 1.63***
6  -25.12 ± 1.79  -47.68 ± 2.53***
8  -37.29 ± 3.48  -53.19 ± 1.72***
10  -27.45 ± 3.48  -42.41 ± 3.24*
12  -15.54 ± 1.22  -34.52 ± 2.56*
***Significant at P<0.001; **significant at P<0.01, *significant at P<0.05 compared 
to gliclazide control
Table 2: Mean percent blood glucose change after 
oral administration of gliclazide alone and gliclazide + 
pravastatin + gemfibrozil combination in diabetic rats 
(n = 6)
Time (h) Gliclazide (1/2 TD) Gliclazide (1/2 TD) + 
Pravastatin (TD)+ 
Gemfibrozil (TD)
0 - -
1 -36.94 * 1.11 -42.70 + 0.72**
2 -37.61 * 0.38 -57.18 + 0.81***
3 -31.35 * 1.85 -46.45 * 0.60***
4 -26.47 * 1.96 -39.67 + 0.83***
6 -36.12 * 1.23 -44.32 + 0.68**
8 -38.12 * 1.47 -56.27 + 0.56***
10 -32.28 * 1.52 -31.70 + 0.86
12 -25.48 * 2.64 -28.02 + 0.70
***Significant at P<0.001; **significant at P<0.01, *significant at P<0.05 compared 
to gliclazide controlJ Young Pharm Vol 2 / No 2  155
The drug profile of gemfibrozil shows that it is a 
highly protein-bound drug, and about 98.6% or greater 
(Hamberger)[18] was bound to plasma proteins. Further, 
gliclazide was reported to interact with highly protein-
bound drugs.[19] Because both gliclazide and gemfibrozil 
are highly protein-bound drugs, gemfibrozil might displace 
other drugs from protein-binding sites, leading to its 
enhanced response. In the presence of the above drugs, 
sustained hypoglycemic activity of gliclazide was observed 
compared to gliclazide control.
CONCLUSION
The interaction was observed in normal and diabetic rats. 
It is likely to occur in humans also. Hence, the combination 
gliclazide (½ TD) + pravastatin (TD) + gemfibrozil (TD) 
should be contraindicated or used with caution in a clinical 
situation.
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